Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of BLD-2660 in Healthy Volunteers and Fibrosis Patients
NCT03559166Phase 1Completed
- Sponsor
- Blade Therapeutics, Inc.
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dazcapistat in pulmonary fibrosis (PF) and Liver Fibrosis (LF) (11 cohorts), sponsored by Blade Therapeutics, Inc. Primary endpoints: Incidence of adverse events at 2 weeks, Any observed changes in clinical safety laboratory results at 2 weeks and 3 more. Started Jul 2018; status: completed.
02
Drugs
dazcapistat
03
Conditions
pulmonary fibrosis (PF)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT03559166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559166.